Annex Advisory Services LLC Purchases 12,745 Shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT)

Annex Advisory Services LLC boosted its position in shares of LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 105.4% during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 24,834 shares of the medical instruments supplier’s stock after purchasing an additional 12,745 shares during the quarter. Annex Advisory Services LLC’s holdings in LeMaitre Vascular were worth $1,410,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. SRS Capital Advisors Inc. boosted its stake in shares of LeMaitre Vascular by 325.5% during the fourth quarter. SRS Capital Advisors Inc. now owns 685 shares of the medical instruments supplier’s stock valued at $39,000 after purchasing an additional 524 shares in the last quarter. DekaBank Deutsche Girozentrale bought a new position in LeMaitre Vascular in the third quarter worth about $38,000. Campbell & CO Investment Adviser LLC lifted its position in LeMaitre Vascular by 78.8% during the third quarter. Campbell & CO Investment Adviser LLC now owns 5,329 shares of the medical instruments supplier’s stock valued at $290,000 after acquiring an additional 2,349 shares during the last quarter. KLR Investment Advisors LLC purchased a new position in LeMaitre Vascular in the fourth quarter worth $351,000. Finally, Quantbot Technologies LP increased its position in shares of LeMaitre Vascular by 709.6% during the third quarter. Quantbot Technologies LP now owns 7,578 shares of the medical instruments supplier’s stock worth $413,000 after purchasing an additional 6,642 shares in the last quarter. 84.64% of the stock is owned by institutional investors.

LeMaitre Vascular Stock Up 3.9 %

Shares of NASDAQ:LMAT traded up $3.01 during midday trading on Wednesday, reaching $80.43. The company’s stock had a trading volume of 151,582 shares, compared to its average volume of 119,710. The stock has a fifty day moving average of $70.87 and a 200 day moving average of $63.34. LeMaitre Vascular, Inc. has a twelve month low of $44.27 and a twelve month high of $81.68. The firm has a market capitalization of $1.81 billion, a PE ratio of 53.27, a P/E/G ratio of 2.39 and a beta of 0.89.

LeMaitre Vascular (NASDAQ:LMAT) last announced its quarterly earnings results on Thursday, May 2nd. The medical instruments supplier reported $0.44 earnings per share for the quarter, topping the consensus estimate of $0.39 by $0.05. The company had revenue of $53.48 million for the quarter, compared to the consensus estimate of $51.50 million. LeMaitre Vascular had a return on equity of 11.57% and a net margin of 16.99%. The firm’s revenue for the quarter was up 13.6% compared to the same quarter last year. During the same period last year, the firm earned $0.27 EPS. Sell-side analysts anticipate that LeMaitre Vascular, Inc. will post 1.77 earnings per share for the current fiscal year.

LeMaitre Vascular Dividend Announcement

The business also recently declared a quarterly dividend, which was paid on Thursday, May 30th. Shareholders of record on Thursday, May 16th were issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.80%. The ex-dividend date was Wednesday, May 15th. LeMaitre Vascular’s payout ratio is presently 42.38%.

Analyst Upgrades and Downgrades

Several research analysts recently issued reports on the company. Stifel Nicolaus raised LeMaitre Vascular from a “hold” rating to a “buy” rating and upped their target price for the company from $59.00 to $75.00 in a research report on Friday, April 26th. Barrington Research increased their price objective on shares of LeMaitre Vascular from $69.00 to $79.00 and gave the company an “outperform” rating in a research report on Friday, May 3rd. StockNews.com downgraded shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Saturday, May 11th. Roth Capital upgraded shares of LeMaitre Vascular to a “strong-buy” rating in a research note on Friday, May 31st. Finally, Roth Mkm reiterated a “buy” rating and set a $100.00 price objective on shares of LeMaitre Vascular in a research note on Friday, May 31st. Three investment analysts have rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $77.57.

Insiders Place Their Bets

In related news, CEO George W. Lemaitre sold 68,906 shares of the firm’s stock in a transaction on Monday, May 6th. The shares were sold at an average price of $75.70, for a total transaction of $5,216,184.20. Following the sale, the chief executive officer now owns 2,133,428 shares in the company, valued at $161,500,499.60. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. In other news, Director John A. Roush sold 7,500 shares of the business’s stock in a transaction that occurred on Thursday, March 7th. The stock was sold at an average price of $69.00, for a total value of $517,500.00. Following the completion of the sale, the director now directly owns 2,278 shares in the company, valued at $157,182. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO George W. Lemaitre sold 68,906 shares of the stock in a transaction that occurred on Monday, May 6th. The shares were sold at an average price of $75.70, for a total value of $5,216,184.20. Following the transaction, the chief executive officer now owns 2,133,428 shares in the company, valued at approximately $161,500,499.60. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 94,931 shares of company stock worth $7,145,020. Corporate insiders own 10.79% of the company’s stock.

About LeMaitre Vascular

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.